Reed's Inc.
Organization details
- Legal name
- Reed's Inc.
- Former names
- Original Beverage Corp /
- Ownership
- Public
- Status
- Active
- SIC code
- 2086 — Bottled & Canned Soft Drinks & Carbonated Waters
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Norwalk
- Headquarters state / province
- Connecticut
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- REED
- Primary stock exchange
- NYSE American
Identifiers
- SEC CIK
- 0001140215
- EIN
- 35-2177773
Board of directors
-
Cyril Arthur Wallace · Director · CEOSince 2025
-
Jerry Lewin · DirectorSince 2024
-
John Bello · DirectorSince 2023
-
Michael Carl Tu · DirectorSince 2025
-
Norman E. Snyder Jr. · Director · CEOSince 2024
-
Randle Lee Edwards · DirectorSince 2023
-
Rudolf Johannes Maria Bakker · DirectorSince 2025
-
Sam Van · DirectorSince 2024
-
Shufen Deng · DirectorSince 2024
Chief executives
Weak · grade F
Out of 100, from shareholder return, dividends, growth and acquisitions.
Partial: only 20% of the scoring weight is on file.
- Revenue growth 20%
- 0
-10.3% a year in revenue
20% of the scoring weight is on file. Figures cover December 2024 – December 2025.
Director election results
Annual meeting of June 10, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
99.9%
-
99.9%
-
99.9%
-
99.9%
Board connections
2 of this board's directors also sit on 2 other boards.
- via Jerry Lewin
- via Sam Van
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 4, 2025 | Era Regenerative Medicine Ltd 10% owner | Open-market purchase | +1,075,269 | — | — |
| Dec 31, 2024 | Shufen Deng Director | Other | −27,139,519 | — | — |
| Nov 19, 2024 | Shufen Deng Director, 10% owner | Other | +22,478,074 | $1.00 | $22,478,074 |
| Nov 15, 2024 | Zaltzman Leon Michael 10% owner | Open-market sale | −4,537 | $1.11 | $5,036 |
| Nov 14, 2024 | Zaltzman Leon Michael 10% owner | Open-market sale | −5,988 | $1.13 | $6,766 |
| Sep 10, 2024 | Zaltzman Leon Michael 10% owner | Open-market purchase | +531,205 | $1.50 | $796,808 |
| Sep 10, 2024 | John Bello Director | Derivative conversion | +200,000 | $1.50 | $300,000 |
| Sep 10, 2024 | Shufen Deng Director, 10% owner | Open-market purchase | +3,268,795 | $1.50 | $4,903,193 |
| Apr 29, 2024 | Burleson Christopher Scott Officer (CCO) | Open-market purchase | +5,209 | — | — |
| Apr 29, 2024 | Tinnelly Joann Christine Officer (CFO) | Open-market purchase | +17,334 | — | — |
| Apr 29, 2024 | Norman E. Snyder Jr. Director, Officer (CEO) | Open-market purchase | +37,605 | — | — |
| Dec 6, 2023 | John Bello Director, 10% owner | Open-market purchase | +5,000 | $1.80 | $9,000 |
| Nov 28, 2023 | Burleson Christopher Scott Officer (CCO) | Grant or award | +18,160 | — | — |
| Nov 28, 2023 | John Bello Director, 10% owner | Open-market purchase | +5,000 | $2.04 | $10,200 |
| May 25, 2023 | Union Square Park Capital Management, LLC Director, 10% owner, SEE REMARKS | Open-market purchase | +193,424 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.